Technologies Enabling Dendritic Cell Targeting for Autoimmune/Inflammatory Disease Therapy

Share this:
Published: 24 Nov 2017

This edition of the Genetic Technology TOE depicts trends across technologies that enable dendritic cell targeting for autoimmune/inflammatory disease therapy. Respiratory inflammation, myasthenia gravis, systemic lupus erytematosus, and other autoimmune disorders are profiled in the TOE. Recent patents related to dendritic cell targeting for autoimmune diseases have also been profiled. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Dendritic cell targeting, autoimmune diseases, inflammatory disorders, psoriatic inflammation, airway inflammation, immune tolerance, myasthenia gravis, plasmacytoid dendritic cells, systemic lupus erythematosus



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..